102
Participants
Start Date
March 31, 2003
Primary Completion Date
December 31, 2004
Study Completion Date
November 30, 2005
cetuximab
400 mg/m2 IV
oxaliplatin
85 mg/m2 IV
leucovorin
200 mg/m2 IV
5-fluorouracil
400 mg/m2 IV
5-fluorouracil
600 mg/m2 IV
cetuximab
250 mg/m2 IV
ImClone Investigational Site, Armonk
ImClone Investigational Site, Brooklyn
ImClone Investigational Site, East Setauket
ImClone Investigational Site, Philadelphia
ImClone Investigational Site, Clinton
ImClone Investigational Site, Baltimore
ImClone Investigational Site, Richmond
ImClone Investigational Site, Winston-Salem
ImClone Investigational Site, Charleston
ImClone Investigational Site, Atlanta
ImClone Investigational Site, Macon
ImClone Investigational Site, Jacksonville
ImClone Investigational Site, Orlando
ImClone Investigational Site, Boynton Beach
ImClone Investigational Site, Tampa
ImClone Investigational Site, Leesburg
ImClone Investigational Site, Nashville
ImClone Investigational Site, Knoxville
ImClone Investigational Site, Louisville
ImClone Investigational Site, Saint Joseph
ImClone Investigational Site, Bismarck
ImClone Investigational Site, Kansas City
ImClone Investigational Site, Rolla
ImClone Investigational Site, Baton Rouge
ImClone Investigational Site, Little Rock
ImClone Investigational Site, Springdale
ImClone Investigational Site, Ogden
ImClone Investigational Site, Pomona
ImClone Investigational Site, Vista
ImClone Investigational Site, San Diego
ImClone Investigational Site, Fountain Valley
ImClone Investigational Site, Orange
ImClone Investigational Site, Greenbrae
ImClone Investigational Site, Gilroy
ImClone Investigational Site, Hartford
ImClone Investigational Site, Norwalk
ImClone Investigational Site, Stamford
ImClone Investigational Site, Waterbury
ImClone Investigational Site, Hackensack
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Eli Lilly and Company
INDUSTRY